secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001615219-25-000168
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharma appoints CEO, CSO, CBO with $225k salary and 35% bonus
----------------------------------------------------------------------

- Frederick E. Pierce appointed CEO, Dr. Barbara Hibner as CSO, Peter Marschel as CBO effective upon merger closing.
- Each executive receives annual base salary of $225,000 and target annual bonus of 35% of base salary.
- Severance includes $225,000 lump sum plus 9 months COBRA reimbursement if terminated without cause or for good reason.
- Employment agreements incorporate at-will status, restrictive covenants, and eligibility for standard benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000168/0001615219-25-000168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000168/flks-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer